Apnimed Inc.
Organization details
- Legal name
- Apnimed Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- APMD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001745648
- EIN
- 82-1910611
Board of directors
-
Chris Dimitropoulos · DirectorSince 2026
-
Gary Sender · DirectorSince 2026
-
Kevin Robert Lind · Director · Chief Executive OfficerSince 2026
-
Lawrence G. Miller · DirectorSince 2026
-
Paul J. Sekhri · DirectorSince 2026
-
Paul R. Fonteyne · DirectorSince 2026
-
William A. Jones Jr. · DirectorSince 2026
Chief executives
Board connections
5 of this board's directors also sit on 8 other boards. 7 are in the same sector.
-
Amylyx Pharmaceuticals Inc. Same sectorvia Paul R. Fonteyne
-
Annexon Inc. Same sectorvia William A. Jones Jr.
-
Avalo Therapeutics Inc. Same sectorvia Kevin Robert Lind
-
Harmony Biosciences Holdings Inc. Same sectorvia Gary Sender
-
Schrodinger Inc. Same sectorvia Gary Sender
- via Paul J. Sekhri
-
iBio Inc. Same sectorvia Gary Sender
-
vTv Therapeutics Inc. Same sectorvia Paul J. Sekhri
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $5,200,000
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 3, 2026 | Molnar Dennis Patrick Officer (President) | Sold back to the company | −58,014 | — | — |
| Aug 3, 2026 | Lawrence G. Miller Director | Sold back to the company | −92,431 | — | — |
| Aug 3, 2026 | Paul J. Sekhri Director | Open-market purchase | +12,500 | $16.00 | $200,000 |
| Aug 3, 2026 | Lunate Holding RSC Ltd 10% owner | Derivative conversion | +1,001,651 | — | — |
| Aug 3, 2026 | Morningside Venture Investments Ltd 10% owner | Derivative conversion | +6,840,213 | — | — |
| Aug 3, 2026 | Molnar Dennis Patrick Officer (President) | Grant or award | +58,014 | — | — |
| Aug 3, 2026 | Lawrence G. Miller Director | Grant or award | +92,431 | — | — |
| Aug 3, 2026 | Lunate Holding RSC Ltd 10% owner | Derivative conversion | +534,214 | — | — |
| Aug 3, 2026 | Morningside Venture Investments Ltd 10% owner | Other | −6,840,213 | — | — |
| Aug 3, 2026 | Lawrence G. Miller Director | Derivative conversion | +10,845 | — | — |
| Aug 3, 2026 | Lunate Holding RSC Ltd 10% owner | Derivative conversion | +4,006,611 | — | — |
| Aug 3, 2026 | Morningside Venture Investments Ltd 10% owner | Other | +6,840,213 | — | — |
| Aug 3, 2026 | Lawrence G. Miller Director | Sold back to the company | −88,954 | — | — |
| Aug 3, 2026 | Lunate Holding RSC Ltd 10% owner | Derivative conversion | +1,512,480 | $13.50 | $20,418,480 |
| Aug 3, 2026 | Morningside Venture Investments Ltd 10% owner | Open-market purchase | +312,500 | $16.00 | $5,000,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Apnimed Inc.
Who is the CEO of Apnimed Inc.?
Kevin Robert Lind has been Apnimed Inc.'s Chief Executive Officer since July 2026.
How many directors are on Apnimed Inc.'s board?
Apnimed Inc.'s board has 7 directors: Chris Dimitropoulos, Gary Sender, Kevin Robert Lind, Lawrence G. Miller, Paul J. Sekhri, Paul R. Fonteyne and William A. Jones Jr.
Are Apnimed Inc. insiders buying or selling shares?
Over the last 12 months, Apnimed Inc. insiders bought $5.2 million of shares in 2 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="apnimed-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.